|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC1A1 |
Gene summary for SLC1A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC1A1 | Gene ID | 6505 |
| Gene name | solute carrier family 1 member 1 | |
| Gene Alias | DCBXA | |
| Cytomap | 9p24.2 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | P43005 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6505 | SLC1A1 | NAFLD1 | Human | Liver | NAFLD | 2.25e-09 | 1.09e+00 | -0.04 |
| 6505 | SLC1A1 | S41 | Human | Liver | Cirrhotic | 6.78e-04 | 5.12e-01 | -0.0343 |
| 6505 | SLC1A1 | S43 | Human | Liver | Cirrhotic | 4.85e-05 | -1.15e-02 | -0.0187 |
| 6505 | SLC1A1 | HCC1_Meng | Human | Liver | HCC | 2.28e-09 | -2.61e-01 | 0.0246 |
| 6505 | SLC1A1 | HCC2_Meng | Human | Liver | HCC | 5.27e-17 | -1.22e-01 | 0.0107 |
| 6505 | SLC1A1 | Pt13.a | Human | Liver | HCC | 5.99e-07 | -2.52e-01 | 0.021 |
| 6505 | SLC1A1 | Pt14.d | Human | Liver | HCC | 3.96e-06 | -2.51e-01 | 0.0143 |
| 6505 | SLC1A1 | S016 | Human | Liver | HCC | 4.20e-03 | -2.62e-01 | 0.2243 |
| 6505 | SLC1A1 | S027 | Human | Liver | HCC | 1.39e-02 | 4.54e-01 | 0.2446 |
| 6505 | SLC1A1 | S028 | Human | Liver | HCC | 2.04e-04 | 2.55e-01 | 0.2503 |
| 6505 | SLC1A1 | S029 | Human | Liver | HCC | 1.14e-06 | 3.49e-01 | 0.2581 |
| 6505 | SLC1A1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.97e-14 | 8.25e-01 | -0.2116 |
| 6505 | SLC1A1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.21e-02 | 5.76e-01 | -0.2107 |
| 6505 | SLC1A1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 3.13e-15 | 7.67e-01 | -0.2119 |
| 6505 | SLC1A1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 6.09e-04 | 4.77e-01 | -0.0809 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003367411 | Liver | HCC | positive regulation of kinase activity | 230/7958 | 467/18723 | 1.72e-03 | 8.95e-03 | 230 |
| GO:003647312 | Liver | HCC | cell death in response to oxidative stress | 55/7958 | 95/18723 | 1.76e-03 | 9.12e-03 | 55 |
| GO:007259312 | Liver | HCC | reactive oxygen species metabolic process | 124/7958 | 239/18723 | 2.05e-03 | 1.04e-02 | 124 |
| GO:00000411 | Liver | HCC | transition metal ion transport | 59/7958 | 105/18723 | 3.18e-03 | 1.47e-02 | 59 |
| GO:015010411 | Liver | HCC | transport across blood-brain barrier | 50/7958 | 87/18723 | 3.42e-03 | 1.55e-02 | 50 |
| GO:004328012 | Liver | HCC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 70/7958 | 129/18723 | 4.58e-03 | 1.97e-02 | 70 |
| GO:001023211 | Liver | HCC | vascular transport | 50/7958 | 88/18723 | 4.69e-03 | 2.02e-02 | 50 |
| GO:200105612 | Liver | HCC | positive regulation of cysteine-type endopeptidase activity | 79/7958 | 148/18723 | 4.82e-03 | 2.03e-02 | 79 |
| GO:00321471 | Liver | HCC | activation of protein kinase activity | 72/7958 | 134/18723 | 5.61e-03 | 2.33e-02 | 72 |
| GO:007124812 | Liver | HCC | cellular response to metal ion | 101/7958 | 197/18723 | 7.82e-03 | 3.10e-02 | 101 |
| GO:00903131 | Liver | HCC | regulation of protein targeting to membrane | 23/7958 | 36/18723 | 7.85e-03 | 3.11e-02 | 23 |
| GO:000688212 | Liver | HCC | cellular zinc ion homeostasis | 24/7958 | 38/18723 | 8.20e-03 | 3.22e-02 | 24 |
| GO:00067501 | Liver | HCC | glutathione biosynthetic process | 12/7958 | 16/18723 | 8.74e-03 | 3.40e-02 | 12 |
| GO:00432791 | Liver | HCC | response to alkaloid | 62/7958 | 115/18723 | 8.79e-03 | 3.42e-02 | 62 |
| GO:004586213 | Lung | AIS | positive regulation of proteolysis | 73/1849 | 372/18723 | 7.68e-09 | 1.21e-06 | 73 |
| GO:199077812 | Lung | AIS | protein localization to cell periphery | 64/1849 | 333/18723 | 1.42e-07 | 1.48e-05 | 64 |
| GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
| GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
| GO:000697913 | Lung | AIS | response to oxidative stress | 75/1849 | 446/18723 | 2.97e-06 | 1.60e-04 | 75 |
| GO:003367412 | Lung | AIS | positive regulation of kinase activity | 77/1849 | 467/18723 | 4.67e-06 | 2.31e-04 | 77 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC1A1 | SNV | Missense_Mutation | c.1471N>C | p.Ile491Leu | p.I491L | P43005 | protein_coding | tolerated(0.46) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| SLC1A1 | SNV | Missense_Mutation | rs199857691 | c.1288N>A | p.Ala430Thr | p.A430T | P43005 | protein_coding | tolerated(1) | benign(0.057) | TCGA-OL-A6VR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC1A1 | SNV | Missense_Mutation | c.979G>A | p.Ala327Thr | p.A327T | P43005 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC1A1 | SNV | Missense_Mutation | novel | c.1508N>G | p.Tyr503Cys | p.Y503C | P43005 | protein_coding | tolerated(0.09) | probably_damaging(0.94) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SLC1A1 | SNV | Missense_Mutation | rs752394755 | c.256N>A | p.Val86Ile | p.V86I | P43005 | protein_coding | tolerated(0.08) | benign(0.015) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SLC1A1 | SNV | Missense_Mutation | rs748031544 | c.383C>T | p.Ala128Val | p.A128V | P43005 | protein_coding | tolerated(0.38) | benign(0.01) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| SLC1A1 | SNV | Missense_Mutation | c.1013C>A | p.Pro338His | p.P338H | P43005 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| SLC1A1 | SNV | Missense_Mutation | c.443N>T | p.Asn148Ile | p.N148I | P43005 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SLC1A1 | SNV | Missense_Mutation | c.1415N>C | p.Gln472Pro | p.Q472P | P43005 | protein_coding | tolerated(0.12) | benign(0) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SLC1A1 | SNV | Missense_Mutation | c.905N>T | p.Pro302Leu | p.P302L | P43005 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-AG-3592-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | CLOZAPINE | CLOZAPINE | 12873733 | |
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 178101343 | ||
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | WORTMANNIN | WORTMANNIN | 12401608,9502808,14574224 | |
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | PMA | 15707698,9502808,14574224 | ||
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | 178101255 | |||
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | Selective serotonin reuptake inhibitors | 22776887 | ||
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | ETHANOL | ALCOHOL | 14574224 | |
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | inhibitor | 178101344 | ||
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | LIDOCAINE | LIDOCAINE | 12401608 | |
| 6505 | SLC1A1 | TRANSPORTER, CELL SURFACE, DRUGGABLE GENOME | STAUROSPORINE | STAUROSPORINE | 12401608,12759177 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |